» Articles » PMID: 36656503

Management of Fatigue in Patients with Advanced Cancer

Overview
Specialty Oncology
Date 2023 Jan 19
PMID 36656503
Authors
Affiliations
Soon will be listed here.
Abstract

Fatigue is a common and distressing symptom experienced by patients with cancer. It is most common in patients with locally advanced or metastatic incurable disease. It can have profound effects on quality-of-life and physical functioning. In addition to general supportive measures (directed at tackling contributory conditions and comorbidities), a variety of specific interventions have been developed which can be broadly categorised as physical therapies, psychological therapies or medication. There is some evidence that each of these approaches can have benefits in patients with earlier stage disease, those undergoing active treatment and in cancer survivors. The best evidence is for aerobic exercise, yoga, cognitive-behavioural therapy (CBT) and psycho-educational interventions. Less strong evidence supports the use of medications such as methylphenidate or ginseng. In patients with advanced disease, it is likely that the mechanisms of fatigue or the factors contributing to fatigue maintenance may be different. Relatively fewer studies have been undertaken in this group and the evidence is correspondingly weaker. The authors recommend the cautious use of aerobic exercise (e.g. walking) in those who are still mobile. The authors advise considering the use of psycho-educational approaches or CBT in those patients who are able to engage in such forms of therapy. In patients near the end-of-life, the authors advise use of dexamethasone (short-term use) and other pharmacological treatments only on the basis of a clinical trial.

Citing Articles

Effects of Jianpi therapy for cancer-related fatigue:a meta-analysis of randomized controlled trials.

Dai J, Shui H, Wu Y, Zhang H, Li Y, Zhang S Front Oncol. 2025; 15:1512460.

PMID: 39980555 PMC: 11840261. DOI: 10.3389/fonc.2025.1512460.


Network analysis of fatigue symptoms in Chinese patients with advanced cancer.

Hu H, Zhao Y, Luo H, Hao Y, Wang P, Yu L Asia Pac J Oncol Nurs. 2025; 12:100641.

PMID: 39886056 PMC: 11780119. DOI: 10.1016/j.apjon.2024.100641.


Putting Methylphenidate for Cancer-Related Fatigue to Rest?.

Chin-Yee N, Yennurajalingam S, Zimmermann C J Clin Oncol. 2024; 42(20):2363-2366.

PMID: 38771985 PMC: 11520668. DOI: 10.1200/JCO.24.00707.


Methylphenidate Versus Placebo for Treating Fatigue in Patients With Advanced Cancer: Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial.

Stone P, Minton O, Richardson A, Buckle P, Enayat Z, Marston L J Clin Oncol. 2024; 42(20):2382-2392.

PMID: 38757263 PMC: 11227299. DOI: 10.1200/JCO.23.02639.


Feasibility of a physical exercise intervention for patients on a palliative care unit: a critical analysis.

Schwonke I, Freitag N, Aschendorf P, Wucharz K, Thieme J, Appelmann I BMC Palliat Care. 2024; 23(1):58.

PMID: 38418974 PMC: 10900709. DOI: 10.1186/s12904-024-01388-5.


References
1.
Hughes A, Suleman S, Rimes K, Marsden J, Chalder T . Cancer-related fatigue and functional impairment - Towards an understanding of cognitive and behavioural factors. J Psychosom Res. 2020; 134:110127. DOI: 10.1016/j.jpsychores.2020.110127. View

2.
Pearson E, Morris M, di Stefano M, McKinstry C . Interventions for cancer-related fatigue: a scoping review. Eur J Cancer Care (Engl). 2016; 27(1). DOI: 10.1111/ecc.12516. View

3.
Spiegel D, Bloom J, YALOM I . Group support for patients with metastatic cancer. A randomized outcome study. Arch Gen Psychiatry. 1981; 38(5):527-33. DOI: 10.1001/archpsyc.1980.01780300039004. View

4.
Pelzer F, Loef M, Martin D, Baumgartner S . Cancer-related fatigue in patients treated with mistletoe extracts: a systematic review and meta-analysis. Support Care Cancer. 2022; 30(8):6405-6418. PMC: 9213316. DOI: 10.1007/s00520-022-06921-x. View

5.
Corbett T, Groarke A, Devane D, Carr E, Walsh J, McGuire B . The effectiveness of psychological interventions for fatigue in cancer survivors: systematic review of randomised controlled trials. Syst Rev. 2019; 8(1):324. PMC: 6911282. DOI: 10.1186/s13643-019-1230-2. View